Company intelligence / Profile preview

Kurobei

Cincinnati, Ohio, United Stateshomeofpoi.com ↗

Ownership: Private
Development stage: Other

Overview

Kurome Therapeutics is developing small molecule therapies that target dysregulated immune signaling pathways in cancer cells, specifically focusing on dual inhibition of IRAK1/4 and FLT3. Their lead compound is expected to enter Phase 1 clinical trials in the second half of 2024. The approach aims to overcome adaptive resistance mechanisms in hematologic malignancies such as AML and MDS by disrupting multiple survival pathways within cancer cells.

Therapeutic areas: OncologyHematology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Kurobei.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kurobei.

Explore the full profile